PureTech Health Valuation
| PRTC Stock | USD 16.64 0.35 2.06% |
At this time, the company appears to be undervalued. PureTech Health PLC holds a recent Real Value of $23.34 per share. The prevailing price of the company is $16.64. Our model determines the value of PureTech Health PLC from analyzing the company fundamentals such as Operating Margin of (25.90) %, shares outstanding of 24.17 M, and Return On Equity of 0.0944 as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that PureTech Health's price fluctuation is not too volatile at this time. Calculation of the real value of PureTech Health PLC is based on 3 months time horizon. Increasing PureTech Health's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since PureTech Health is currently traded on the exchange, buyers and sellers on that exchange determine the market value of PureTech Stock. However, PureTech Health's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 16.64 | Real 23.34 | Hype 16.62 | Naive 15.95 |
The real value of PureTech Stock, also known as its intrinsic value, is the underlying worth of PureTech Health PLC Company, which is reflected in its stock price. It is based on PureTech Health's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of PureTech Health's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of PureTech Health PLC helps investors to forecast how PureTech stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of PureTech Health more accurately as focusing exclusively on PureTech Health's fundamentals will not take into account other important factors: PureTech Health Total Value Analysis
PureTech Health PLC is at this time anticipated to have valuation of 116.2 M with market capitalization of 402.16 M, debt of 22.36 M, and cash on hands of 368.03 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the PureTech Health fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
116.2 M | 402.16 M | 22.36 M | 368.03 M |
PureTech Health Investor Information
The company has price-to-book ratio of 1.09. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. PureTech Health PLC had not issued any dividends in recent years. PureTech Health PLC is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.PureTech Health Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. PureTech Health has an asset utilization ratio of 0.8 percent. This indicates that the Company is making $0.008011 for each dollar of assets. An increasing asset utilization means that PureTech Health PLC is more efficient with each dollar of assets it utilizes for everyday operations.PureTech Health Ownership Allocation
PureTech Health owns a total of 24.17 Million outstanding shares. Roughly 99.58 pct. of PureTech Health outstanding shares are held by general public with 0.42 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.PureTech Health Profitability Analysis
The company reported the previous year's revenue of 4.83 M. Net Income was 27.78 M with loss before overhead, payroll, taxes, and interest of (48.81 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates PureTech Health's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in PureTech Health and how it compares across the competition.
About PureTech Health Valuation
The stock valuation mechanism determines PureTech Health's current worth on a weekly basis. Our valuation model uses a comparative analysis of PureTech Health. We calculate exposure to PureTech Health's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of PureTech Health's related companies.PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. PureTech Health operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 95 people.
PureTech Health Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 27 M | |
| Quarterly Earnings Growth Y O Y | 0.615 |
Complementary Tools for PureTech Stock analysis
When running PureTech Health's price analysis, check to measure PureTech Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PureTech Health is operating at the current time. Most of PureTech Health's value examination focuses on studying past and present price action to predict the probability of PureTech Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PureTech Health's price. Additionally, you may evaluate how the addition of PureTech Health to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |